Developer docs
API playgroundTry for free, no card

Search company profiles

SeaBeLife

Full company profile

uuid00005mj

Namestring
SeaBeLife
Legal namestring
SeaBeLife Biotech
Websiteurl
seabelife.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

SeaBeLife is a French pre-clinical biotechnology company founded in March 2019 in Roscoff, Brittany, by CEO Morgane Rousselot (PhD in Biochemistry, UPMC-CNRS-Station Biologique de Roscoff) and CTO Claire Delehouzé (Biotechnology Engineer). The company develops first-in-class small-molecule drug candidates that simultaneously inhibit two regulated cell-death pathways, necroptosis and ferroptosis, anchored on the lead molecule sibiriline (a RIPK1 kinase inhibitor with radical-trapping antioxidant activity). SeaBeLife's pipeline comprises SBL01, an IV-administered candidate for acute liver failure that received EMA Orphan Drug Designation in September 2024; SBL03, a topical ophthalmic gel for geographic atrophy (dry AMD) that showed promising preclinical in vivo results in January 2025; and the earlier-stage SBL-OX family targeting neurodegenerative diseases including Parkinson's. Discovery is enabled by proprietary marine-derived molecule libraries sourced through a research partnership with the Roscoff Biological Station.

The business operates on a licensing-and-co-development model. SeaBeLife is currently pre-revenue, with no approved or commercialized products. Future revenue is expected to come from out-licensing candidates to large pharmaceutical partners, generating milestone payments during clinical development and royalties upon commercialization. Commercial traction to date is reflected in the December 2025 joint development agreement with Unither Pharmaceuticals for SBL03 formulation and production, alongside consistent capital inflows including approximately €8 million raised since inception from Bpifrance (€1.37M deep-tech grant, 2022), the France 2030 / i-Nov program (€1.5M, April 2024), and a €2M pre-Series A round led by iXLife (October 2025), with multiple Breton and Parisian business angel networks as co-investors. Customers are effectively future enterprise pharmaceutical partners rather than end patients, with first clinical trials targeted for 2026-2027.

Short descriptiontext

SeaBeLife is a French pre-clinical biotech developing first-in-class small molecules that simultaneously inhibit necroptosis and ferroptosis, with lead candidates SBL01 for acute liver failure and SBL03 for geographic atrophy (dry AMD), pursuing a licensing-based business model targeting pharmaceutical partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRoscoff, France
HQ citystring
Roscoff
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regulated cell death therapeutics, necroptosis ferroptosis inhibitors, ophthalmic drug development, acute liver failure therapy, marine derived drug discovery
Industry2 codes
PRIMARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAI
RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
Pre-clinical biopharmaceutical drug development
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Licensing Revenue
TypeLicensing Royalties
Description

Pre-revenue biotech company. Future revenue expected from licensing drug candidates to pharmaceutical partners, generating milestone payments during development and royalty payments upon commercialization.

Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

SeaBeLife develops proprietary small-molecule drug candidates that simultaneously block two regulated cell death pathways — necroptosis and ferroptosis — to treat acute, rare, and chronic diseases of major organs. Its lead assets are SBL03, a topical ophthalmic gel for geographic atrophy (dry AMD), and SBL01, an intravenous therapy for acute liver failure that holds EMA Orphan Drug Designation, with earlier-stage programs in neurodegenerative indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Orphan Drug Designation granted by EMA for acute liver failure indication
Product overview1 text field

SeaBeLife is a biotechnology company developing two families of patented small molecule drug candidates designed to block regulated necrosis (programmed cell death). The company's first-in-class approach simultaneously targets two major regulated cell death pathways — necroptosis and ferroptosis — addressing major unmet medical needs in acute, rare, and chronic indications. The lead products are SBL03 (ophthalmic gel for geographic atrophy/dry AMD) and SBL01 (IV formulation for acute liver failure), with SBL-OX programs targeting neurodegenerative diseases in earlier development stages. The platform is anchored by the lead molecule sibiriline, which uniquely inhibits both pathways.

Product and service3 records
1SBL01
CategoryDrug candidate — hepatology (acute liver failure)
Description

SBL01 is a first-in-class small-molecule dual inhibitor of necroptosis and ferroptosis administered intravenously for the treatment of acute liver failure. It received Orphan Drug Designation from the European Medicines Agency in September 2024.

2SBL03
CategoryDrug candidate — ophthalmology (dry AMD / geographic atrophy)
Description

SBL03 is a dual necroptosis/ferroptosis inhibitor formulated as a topical ophthalmic gel for non-invasive delivery to the eye, intended to treat geographic atrophy in dry age-related macular degeneration (dry AMD). It showed promising preclinical in vivo efficacy in early 2025 and is planned to enter clinical trials in 2026.

3SBL-OX / SBL-OXs
CategoryDrug candidate — neurodegenerative diseases (preclinical)
Description

SBL-OX / SBL-OXs is a family of preclinical dual necroptosis/ferroptosis inhibitor drug candidates being developed for neurodegenerative diseases, including Parkinson's disease. The program is described as 'Drug Discovery in progress' in SeaBeLife's pipeline.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-08
Description

Joint development agreement for ophthalmic drug candidate. Unither Pharmaceuticals, a pharmaceutical development and manufacturing company, is collaborating with SeaBeLife on the development of their ophthalmic drug candidate, representing a key strategic partnership for advancing the pipeline toward clinical stages.

2Roscoff Biological Station
Strategic tierMinorTypeOthers
Description

Research partnership for marine biotechnology research and access to marine biological resources for drug discovery purposes.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Apellis developed and commercializes pegcetacoplan (Syfovre), the first FDA-approved treatment for geographic atrophy secondary to dry AMD. It is highly comparable as a direct competitor in SeaBeLife's SBL03 indication, though it is significantly larger and commercially active.

TypeBroad incumbent
Description

Iveric Bio developed avacincaptad pegol (Izervay) for GA, now owned by Astellas. It is a direct competitor to SeaBeLife's SBL03 in geographic atrophy and represents the established second-mover standard of care in the indication.

3Rigel Pharmaceuticals
TypeDirect peer
Description

Rigel has pioneered clinical-stage RIPK1/necroptosis inhibitor programs (e.g., fostamatinib and earlier-stage candidates). It is one of the closest mechanistic comparables to SeaBeLife in the regulated necrosis pathway, though focused on immunology and hematology.

TypeDirect peer
Description

Genfit is a French-listed biotech developing small molecule therapies for liver diseases including acute and chronic hepatic conditions. It is highly comparable to SeaBeLife as a French specialty liver biotech at a similar stage of pipeline development.

TypeEmerging player
Description

Alkeus is developing treatments for retinal degenerative diseases including Stargardt disease and geographic atrophy. It is comparable to SeaBeLife as a focused ophthalmology biotech targeting serious retinal conditions with high unmet need.

TypeEmerging player
Description

NGM Biopharmaceuticals has developed small molecule therapies for retinal and metabolic diseases, including earlier-stage dry AMD programs. It shares SeaBeLife's approach of using small molecules to address ophthalmology indications with high unmet need.

TypeDirect peer
Description

CytoSorbents develops blood purification therapies used in critical care settings including acute liver failure and sepsis. It is comparable to SeaBeLife's SBL01 program in addressing acute liver failure with novel therapeutic approaches.

TypeBroad incumbent
Description

BioMarin is a global leader in rare disease and orphan specialty pharmaceuticals. It is broadly comparable to SeaBeLife as a benchmark for orphan drug commercial economics, particularly relevant to SBL01's acute liver failure ODD pathway.

TypeBroad incumbent
Description

Vertex is a leading small molecule specialty biotech developing transformative therapies for serious diseases. It is broadly comparable to SeaBeLife as a benchmark for value creation from small molecule platforms in specialty and rare disease indications.

TypeEmerging player
Description

Inflection Biosciences is an early-stage biotech working on novel cell death pathway inhibitors including ferroptosis modulators. It is comparable to SeaBeLife as a peer developer of regulated cell death pathway therapeutics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SeaBeLife

Pre-clinical biopharmaceutical drug developmentseabelife.com

SeaBeLife is a French pre-clinical biotech developing first-in-class small molecules that simultaneously inhibit necroptosis and ferroptosis, with lead candidates SBL01 for acute liver failure and SBL03 for geographic atrophy (dry AMD), pursuing a licensing-based business model targeting pharmaceutical partners.

What SeaBeLife does

SeaBeLife is a French pre-clinical biotechnology company founded in March 2019 in Roscoff, Brittany, by CEO Morgane Rousselot (PhD in Biochemistry, UPMC-CNRS-Station Biologique de Roscoff) and CTO Claire Delehouzé (Biotechnology Engineer). The company develops first-in-class small-molecule drug candidates that simultaneously inhibit two regulated cell-death pathways, necroptosis and ferroptosis, anchored on the lead molecule sibiriline (a RIPK1 kinase inhibitor with radical-trapping antioxidant activity). SeaBeLife's pipeline comprises SBL01, an IV-administered candidate for acute liver failure that received EMA Orphan Drug Designation in September 2024; SBL03, a topical ophthalmic gel for geographic atrophy (dry AMD) that showed promising preclinical in vivo results in January 2025; and the earlier-stage SBL-OX family targeting neurodegenerative diseases including Parkinson's. Discovery is enabled by proprietary marine-derived molecule libraries sourced through a research partnership with the Roscoff Biological Station.

The business operates on a licensing-and-co-development model. SeaBeLife is currently pre-revenue, with no approved or commercialized products. Future revenue is expected to come from out-licensing candidates to large pharmaceutical partners, generating milestone payments during clinical development and royalties upon commercialization. Commercial traction to date is reflected in the December 2025 joint development agreement with Unither Pharmaceuticals for SBL03 formulation and production, alongside consistent capital inflows including approximately €8 million raised since inception from Bpifrance (€1.37M deep-tech grant, 2022), the France 2030 / i-Nov program (€1.5M, April 2024), and a €2M pre-Series A round led by iXLife (October 2025), with multiple Breton and Parisian business angel networks as co-investors. Customers are effectively future enterprise pharmaceutical partners rather than end patients, with first clinical trials targeted for 2026-2027.

SeaBeLife firmographics

Firmographics
Name
SeaBeLife
Legal name
SeaBeLife Biotech
Website
https://seabelife.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
SeaBeLife is a French pre-clinical biotech developing first-in-class small molecules that simultaneously inhibit necroptosis and ferroptosis, with lead candidates SBL01 for acute liver failure and SBL03 for geographic atrophy (dry AMD), pursuing a licensing-based business model targeting pharmaceutical partners.
Ownership category
akta.pro rank

SeaBeLife industry classification

Industry
Product category
Pre-clinical biopharmaceutical drug development
NAICS
Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAI
RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Regulated cell death therapeutics
  • Necroptosis ferroptosis inhibitors
  • Ophthalmic drug development
  • Acute liver failure therapy
  • Marine derived drug discovery

Where SeaBeLife is headquartered

Location

Headquarters

HQ city
Roscoff
HQ country
France
HQ region
Europe

Offices1 record

Markets served

SeaBeLife business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Licensing Revenue: Pre-revenue biotech company. Future revenue expected from licensing drug candidates to pharmaceutical partners, generating milestone payments during development and royalty payments upon commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

SeaBeLife product offering

Product offering

Core offering

SeaBeLife develops proprietary small-molecule drug candidates that simultaneously block two regulated cell death pathways — necroptosis and ferroptosis — to treat acute, rare, and chronic diseases of major organs. Its lead assets are SBL03, a topical ophthalmic gel for geographic atrophy (dry AMD), and SBL01, an intravenous therapy for acute liver failure that holds EMA Orphan Drug Designation, with earlier-stage programs in neurodegenerative indications.

Product overview

SeaBeLife is a biotechnology company developing two families of patented small molecule drug candidates designed to block regulated necrosis (programmed cell death). The company's first-in-class approach simultaneously targets two major regulated cell death pathways — necroptosis and ferroptosis — addressing major unmet medical needs in acute, rare, and chronic indications. The lead products are SBL03 (ophthalmic gel for geographic atrophy/dry AMD) and SBL01 (IV formulation for acute liver failure), with SBL-OX programs targeting neurodegenerative diseases in earlier development stages. The platform is anchored by the lead molecule sibiriline, which uniquely inhibits both pathways.

Differentiator

Problem solved

Functional benefit

Products and services

  • SBL01 SBL01 is a first-in-class small-molecule dual inhibitor of necroptosis and ferroptosis administered intravenously for the treatment of acute liver failure. It received Orphan Drug Designation from the European Medicines Agency in September 2024.
  • SBL03 SBL03 is a dual necroptosis/ferroptosis inhibitor formulated as a topical ophthalmic gel for non-invasive delivery to the eye, intended to treat geographic atrophy in dry age-related macular degeneration (dry AMD). It showed promising preclinical in vivo efficacy in early 2025 and is planned to enter clinical trials in 2026.
  • SBL-OX / SBL-OXs SBL-OX / SBL-OXs is a family of preclinical dual necroptosis/ferroptosis inhibitor drug candidates being developed for neurodegenerative diseases, including Parkinson's disease. The program is described as 'Drug Discovery in progress' in SeaBeLife's pipeline.

Quantifiable outcome

  • Orphan Drug Designation granted by EMA for acute liver failure indication

Companies that use SeaBeLife

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles1 record

SeaBeLife technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

SeaBeLife partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Unither PharmaceuticalscoreStrategic or Co-development Partner · 8 December 2025Joint development agreement for ophthalmic drug candidate. Unither Pharmaceuticals, a pharmaceutical development and manufacturing company, is collaborating with SeaBeLife on the development of their ophthalmic drug candidate, representing a key strategic partnership for advancing the pipeline toward clinical stages.
  • Roscoff Biological StationminorOthersResearch partnership for marine biotechnology research and access to marine biological resources for drug discovery purposes.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

SeaBeLife competitors and assessment

Company assessment

Broad incumbents

  • Apellis Pharmaceuticals: Apellis developed and commercializes pegcetacoplan (Syfovre), the first FDA-approved treatment for geographic atrophy secondary to dry AMD. It is highly comparable as a direct competitor in SeaBeLife's SBL03 indication, though it is significantly larger and commercially active.
  • Iveric Bio (Astellas): Iveric Bio developed avacincaptad pegol (Izervay) for GA, now owned by Astellas. It is a direct competitor to SeaBeLife's SBL03 in geographic atrophy and represents the established second-mover standard of care in the indication.
  • BioMarin Pharmaceutical: BioMarin is a global leader in rare disease and orphan specialty pharmaceuticals. It is broadly comparable to SeaBeLife as a benchmark for orphan drug commercial economics, particularly relevant to SBL01's acute liver failure ODD pathway.
  • Vertex Pharmaceuticals: Vertex is a leading small molecule specialty biotech developing transformative therapies for serious diseases. It is broadly comparable to SeaBeLife as a benchmark for value creation from small molecule platforms in specialty and rare disease indications.

Direct peers

  • Rigel Pharmaceuticals: Rigel has pioneered clinical-stage RIPK1/necroptosis inhibitor programs (e.g., fostamatinib and earlier-stage candidates). It is one of the closest mechanistic comparables to SeaBeLife in the regulated necrosis pathway, though focused on immunology and hematology.
  • Genfit: Genfit is a French-listed biotech developing small molecule therapies for liver diseases including acute and chronic hepatic conditions. It is highly comparable to SeaBeLife as a French specialty liver biotech at a similar stage of pipeline development.
  • CytoSorbents: CytoSorbents develops blood purification therapies used in critical care settings including acute liver failure and sepsis. It is comparable to SeaBeLife's SBL01 program in addressing acute liver failure with novel therapeutic approaches.

Emerging players

  • Alkeus Pharmaceuticals: Alkeus is developing treatments for retinal degenerative diseases including Stargardt disease and geographic atrophy. It is comparable to SeaBeLife as a focused ophthalmology biotech targeting serious retinal conditions with high unmet need.
  • NGM Biopharmaceuticals: NGM Biopharmaceuticals has developed small molecule therapies for retinal and metabolic diseases, including earlier-stage dry AMD programs. It shares SeaBeLife's approach of using small molecules to address ophthalmology indications with high unmet need.
  • Inflection Biosciences: Inflection Biosciences is an early-stage biotech working on novel cell death pathway inhibitors including ferroptosis modulators. It is comparable to SeaBeLife as a peer developer of regulated cell death pathway therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

SeaBeLife social profiles

Digital presence

SeaBeLife compliance and trust

Trust signal

Compliance1 record

SeaBeLife financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SeaBeLife leadership team

Management profile

Number of profiles

Profiles2 records

SeaBeLife funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SeaBeLife M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SeaBeLife

What does SeaBeLife do?

SeaBeLife develops proprietary small-molecule drug candidates that simultaneously block two regulated cell death pathways — necroptosis and ferroptosis — to treat acute, rare, and chronic diseases of major organs. Its lead assets are SBL03, a topical ophthalmic gel for geographic atrophy (dry AMD), and SBL01, an intravenous therapy for acute liver failure that holds EMA Orphan Drug Designation, with earlier-stage programs in neurodegenerative indications.

Is SeaBeLife a public or private company?

SeaBeLife is a private company. It is classified as venture growth investor backed and is currently operating.

When was SeaBeLife founded?

SeaBeLife was founded in 2019. It employs 11 to 50 people.

Where is SeaBeLife based?

SeaBeLife is headquartered in Roscoff, France, in the Europe region.

How does SeaBeLife make money?

One revenue line is on record: licensing Revenue.

Who are SeaBeLife's main competitors?

Broad incumbents on record are Apellis Pharmaceuticals, Iveric Bio (Astellas), BioMarin Pharmaceutical and Vertex Pharmaceuticals. Direct peers are Rigel Pharmaceuticals, Genfit and CytoSorbents. Emerging players are Alkeus Pharmaceuticals, NGM Biopharmaceuticals and Inflection Biosciences.

Does SeaBeLife have an API?

No public API is recorded for SeaBeLife.

What industry is SeaBeLife in?

SeaBeLife's product category is Pre-clinical biopharmaceutical drug development. Its primary akta.pro industry code is HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification), with a secondary code of HLAAADAI, RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
VestbeeSeaBeLife lands €2.9M to advance liver disease drug candidateSeaBeLife received €2.9M in government funding to advance its SBL01 drug candidate for acute liver damage. The funding supports the €6.47M SeaBeLIVER project, which includes a Phase I trial in healthy volunteers and a Phase Ib trial in hospitalized patients. The project is expected to run from 2026 to 2028.Business & FinancialSeaBeLife awarded €2.9 million in government funding to generate initial clinical data for its drug candidateSeaBeLife received €2.9 million in government funding under France 2030 to advance its SBL01 drug candidate for acute liver injury. The project covers preclinical studies and a phase I trial in healthy volunteers, followed by a phase Ib trial in hospitalized patients. SBL01 has already received orphan drug designation in the EU.PharmiWeb.comSeaBeLife welcomes Professor Eric Souied to its scientific committeeSeaBeLife, a French biotechnology company developing drug candidates to block cellular necrosis, has announced the appointment of Professor Eric Souied to its scientific committee. Professor Souied, an international expert in age-related macular degeneration (AMD) and Head of Ophthalmology at Henri Mondor Hospital in Créteil, will guide the scientific approach to SeaBeLife's ophthalmology program targeting necroptosis and ferroptosis in retinal degeneration. The company is also conducting discussions with potential partners to advance the program, following promising preclinical efficacy results for SBL03 in geographic atrophy delivered in early 2025.PharmiWeb.comSeaBeLife enters into joint development agreement with Unither Pharmaceuticals to formulate and produce ophthalmic drug candidateSeaBeLife, a French biotechnology company developing drug candidates to block cellular necrosis, has signed a joint development agreement with Unither Pharmaceuticals, a French pharmaceutical CDMO, to formulate and produce the topical ophthalmic formulation of its SBL03 drug candidate for treating degenerative retinal disorders. The partnership covers pharmaceutical development, industrial scale-up, and GMP batch manufacturing, with the goal of starting Phase 1 clinical trials in 2027 for geographic atrophy and dry age-related macular degeneration. SeaBeLife retains ownership of the drug candidate while Unither handles the pharmaceutical development and manufacture, combining scientific expertise with industrial capabilities.PharmiWeb.comSeaBeLife enters into joint development agreement with Unither Pharmaceuticals to formulate and produce ophthalmic drug candidateSeaBeLife, a French biotechnology company, has signed a joint development agreement with Unither Pharmaceuticals to formulate and produce clinical and commercial batches of its SBL03 drug candidate for treating degenerative retinal disorders such as geographic atrophy and dry age-related macular degeneration. The partnership combines SeaBeLife's scientific expertise in targeting necroptosis and ferroptosis pathways with Unither's pharmaceutical manufacturing capabilities, with the goal of starting Phase 1 clinical trials in 2027. The agreement covers formulation development, industrial scale-up, GMP batch manufacturing, and preparation of the Chemistry, Manufacturing, and Controls application for regulatory submission.The Pharma LetterSeaBeLife enters deal with Unither to develop SBL03French biotech company SeaBeLife has entered a partnership agreement with Unither for the development and manufacturing of SBL03, a topical ophthalmic drug candidate intended to treat degenerative retinal disorders such as geographic atrophy and dry age-related macular degeneration. The agreement covers pharmaceutical development, industrial scale-up, manufacture of preclinical and GMP batches, and preparation of the CMC application for regulatory submission ahead of Phase I clinical trials planned for 2027. SeaBeLife retains ownership of the drug candidate while Unither is entrusted with pharmaceutical development and manufacturing, combining the scientific expertise of SeaBeLife with Unither's pharmaceutical capabilities.Pulse 2.0SeaBeLife: €2 Million Pre-Series A Secured To Advance Clinical Trials In Dry AMD And Severe Acute HepatitisSeaBeLife, a biotechnology company developing drug candidates to inhibit cellular necrosis, has closed a pre-Series A funding round raising €2 million ($2.25 million), with iXLife as the lead investor alongside Breizh Angels, WeLikeStartup, Angels Santé, Business Angels des Grandes Ecoles, INEXT, and Femmes Business Angels. The funding will support clinical trials for two lead drug programs targeting dry age-related macular degeneration (AMD) and severe acute hepatitis, with the company targeting its first clinical trial in 2026. New strategic investors INEXT and Femmes Business Angels were onboarded, with Marie-Pierre Sbardella joining the SeaBeLife Strategic Committee, and the company is preparing for a subsequent Series A round to sustain development momentum.Tech.euFrench biotech SeaBeLife raises €2M to treat liver and eye diseasesSeaBeLife raised €2 million in pre-Series A funding led by iXLife, with new investors INEXT and Femmes Business Angels. The funds will support drug development for dry AMD and severe acute hepatitis, with clinical trials expected in 2026. The company has now raised €9 million total and is preparing for a larger Series A round.StartupriseSeaBeLife Secures €2M To Advance Therapies For Liver And Eye DiseasesFrench biotech company SeaBeLife has raised €2 million in a pre-Series A funding round led by existing investor iXLife, with participation from new backers including INEXT and Femmes Business Angels. The funding will advance two lead therapeutic programs targeting dry age-related macular degeneration and severe acute hepatitis, with first clinical trials planned for 2026. The company is developing first-in-class small molecules that block necroptosis and ferroptosis—two regulated cell death pathways—and is preparing for a larger Series A round to fund clinical trials and scale its pipeline.PharmiWeb.comSeaBeLife secures €2 millionSeaBeLife, a biotechnology company developing drug candidates to block cellular necrosis, has secured €2 million in a pre-Series A funding round led by iXLife with participation from Breizh Angels, WeLikeStartup, Angels Santé, Business Angels des Grandes Ecoles, INEXT, and Femmes Business Angels. The financing will support the launch of clinical trials for two drug candidates targeting dry age-related macular degeneration and severe acute hepatitis, with the first clinical trial scheduled to begin in 2026. Founded in 2019 and based in Roscoff, France, SeaBeLife has now raised a total of €9 million and is preparing for a Series A funding round to sustain further development.